Trails Edge Capital Partners, LP
Position in DSGN — Design Therapeutics, Inc.
CIK 2077247
ATLANTA, GA
Position in DSGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$28,958,550
+$19,893,132 QoQ
Shares Held
2,001,282
+134.9% QoQ
Ownership
3.20%
of shares outstanding
% of Portfolio
4.60%
of 13F equity value
Holder Rank
#7
of 136 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DSGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Trails Edge Capital Partners, LP holds $624,561,875 across 34 Biotechnology names. DSGN ranks #7 (4.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LBRX |
Lb Pharmaceuticals Inc
|
1,523,022 | $49,429,679 | |
| 2 | NRIX |
Nurix Therapeutics, Inc.
|
1,573,220 | $38,166,317 | |
| 3 | IMCR |
Immunocore Holdings plc
|
1,063,234 | $33,757,679 | |
| 4 | TRAX |
First Tracks Biotherapeutics, Inc.
|
1,514,000 | $30,461,680 | |
| 5 | FDMT |
4D Molecular Therapeutics, Inc.
|
2,227,917 | $29,631,296 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
512,000 | $29,296,640 | |
| 7 | DSGN |
Design Therapeutics, Inc.
This page
|
2,001,282 | $28,958,550 | |
| 8 | XENE |
Xenon Pharmaceuticals Inc.
|
440,000 | $26,558,400 |
All Filings in DSGN
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $28,958,550 | 2,001,282 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $9,065,418 | 852,013 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||